Clinical Trials Logo

Mental Disorders clinical trials

View clinical trials related to Mental Disorders.

Filter by:

NCT ID: NCT00128479 Completed - Clinical trials for Major Depressive Disorder

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

Start date: September 2004
Phase: Phase 3
Study type: Interventional

Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this 56 day study is to learn the safety and effectiveness of Corlux in patients who have been diagnosed with psychotic major depression (PMD).

NCT ID: NCT00125138 Completed - Parkinson's Disease Clinical Trials

Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease. Subjects will be enrolled at approximately 20 investigational sites in the United States (U.S.) and 15 Ex-US sites. The maximum study duration will be 10 weeks. Subjects will have the option of continuing in an open-label extension study.

NCT ID: NCT00109642 Completed - Mental Disorders Clinical Trials

The Role of Norepinephrine in Emotional Processing

Start date: April 26, 2005
Phase: N/A
Study type: Observational

This study will examine the role of a brain chemical called norepinephrine in thinking, decision-making, and emotional processing. After norepinephrine is released from a brain cell, it binds to another brain cell's receptor. Some of the receptors it binds to are called alpha-2 adrenergic receptors. This study will use medicines called yohimbine and guanfacine to look at the function of norepinephrine in the brain when it binds to the alpha-2 adrenergic receptors. Yohimbine increases norepinephrine's function and guanfacine decreases its function. Healthy volunteers between 20 and 50 years of age who do not have heart disease, high blood pressure, psychiatric illness, or other serious medical conditions and who are not allergic to lactose may be eligible for this study. Candidates are screened with a medical and psychiatric history, physical examination, neuropsychological testing, blood and urine tests and electrocardiogram. Women are screened with a urine pregnancy test. Participants are given a pill of yohimbine, guanfacine, or placebo and undergo the following tests and procedures: - Blood pressure and heart rate measurements: Blood pressure and heart rate are measured before the medication is taken and several times after. - Blood draws: Blood is drawn before the medicine is taken and 90 minutes after to measure levels of norepinephrine and the hormone cortisol. - Neurocognitive testing: Participants do neurocognitive tasks on the computer for up to 90 minutes. The tasks involve looking at pictures or words on a screen and responding according to instructions given. - Magnetic resonance imaging (MRI): Patients may undergo neurocognitive testing MRIs. This test uses a strong magnetic field and radio waves to show changes in brain activity. The subject lies on a table that slides into a narrow cylinder (the MRI scanner). Images of the brain are obtained while the subject performs the computer tasks.

NCT ID: NCT00108368 Completed - Schizophrenia Clinical Trials

The Effects of Risperidone and Olanzapine on Thinking

Start date: October 2003
Phase: Phase 4
Study type: Interventional

The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition. Hypothesis: Risperidone and olanzapine will show greater benefits than conventional medications on assessments of social cognition, particularly affect perception and social perception.

NCT ID: NCT00105794 Completed - Schizophrenia Clinical Trials

Psychiatric Advance Directives for Improved Mental Health Care

Start date: March 2004
Phase: N/A
Study type: Interventional

During a psychiatric crisis, persons with severe mental illness (SMI) confront complex challenges concerning treatment choices and are often ill equipped or unable to make mental health care decisions. Psychiatric Advance Directives (PADs) are legal documents that allow competent persons to declare their treatment preferences in advance of a mental health crisis, when they may lose capacity to make reliable health care decisions. The use of PADs is consistent with recommendations of the President�s New Freedom Commission on Mental Illness and the Patient Self-Determination Act; 25 states have now adopted PAD legislation. VA does not have a specific policy for PADs or mechanisms to notify veterans of their right to prepare PADs. The downstream effects of PADs on patient care, crisis management, service use, and clinical outcomes are unknown.

NCT ID: NCT00104195 Completed - Anxiety Disorders Clinical Trials

A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions

Start date: February 2004
Phase: Phase 1
Study type: Observational

The purpose of this trial is to study how teens with and without an anxiety disorder make decisions. This is a brain imaging study using functional magnetic resonance imaging (fMRI) in adolescents between the ages of 13 and 17.

NCT ID: NCT00104039 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Brain Changes in Children and Adolescents With Behavioral Problems

Start date: February 17, 2005
Phase:
Study type: Observational

Purpose: This study will examine brain activity in children age 10-18 with disruptive behavior problems, including conduct disorder (CD), oppositional defiant disorder (ODD), and attention deficit hyperactivity disorder (ADHD), compared with children without behavioral problems. Our goal is to examine differences in how emotions, social situations, and problem-solving situations are processed in the brain across these groups of children.

NCT ID: NCT00100542 Completed - HIV Infections Clinical Trials

Psychiatric Problems in Children and Adolescents Infected With HIV at Birth

Start date: April 2005
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether HIV and anti-HIV drugs cause mental health problems or make mental health problems worse in children and adolescents who were infected with HIV at birth.

NCT ID: NCT00095810 Completed - Parkinson's Disease Clinical Trials

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Start date: July 2003
Phase: Phase 4
Study type: Interventional

The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

NCT ID: NCT00095524 Completed - Schizophrenia Clinical Trials

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Start date: March 2004
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.